MetaVia Future Growth

Future criteria checks 0/6

MetaVia's earnings are forecast to decline at 31.3% per annum. EPS is expected to grow by 10.3% per annum.

Key information

-31.3%

Earnings growth rate

10.3%

EPS growth rate

Biotechs earnings growth	26.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	Low
Last updated	30 Dec 2024

Recent future growth updates

Recent updates

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Oct 03

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

Sep 29

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

Sep 14

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

Sep 12

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

Nov 25

NeuroBo on track to post a record gain after announcing a special meeting

Jun 14

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Jan 06

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

Dec 21

NeuroBo Pharmaceuticals EPS misses by $0.02

Nov 13

Earnings and Revenue Growth Forecasts

NasdaqCM:MTVA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	N/A	-72	N/A	N/A	3
12/31/2026	N/A	-44	N/A	N/A	4
12/31/2025	N/A	-29	N/A	-36	4
12/31/2024	N/A	-30	N/A	-27	4
9/30/2024	N/A	-28	-23	-23	N/A
6/30/2024	N/A	-26	-20	-20	N/A
3/31/2024	N/A	-17	-15	-15	N/A
12/31/2023	N/A	-12	-11	-11	N/A
9/30/2023	N/A	-12	-9	-9	N/A
6/30/2023	N/A	-11	-9	-9	N/A
3/31/2023	N/A	-14	-9	-9	N/A
12/31/2022	N/A	-14	-12	-12	N/A
9/30/2022	N/A	-14	-13	-13	N/A
6/30/2022	N/A	-14	-13	-13	N/A
3/31/2022	N/A	-15	-14	-14	N/A
12/31/2021	N/A	-15	-15	-15	N/A
9/30/2021	N/A	-30	-15	-15	N/A
6/30/2021	N/A	-30	-14	-14	N/A
3/31/2021	N/A	-28	-13	-13	N/A
12/31/2020	N/A	-30	-11	-11	N/A
9/30/2020	N/A	-23	-10	-10	N/A
6/30/2020	N/A	-24	-11	-11	N/A
3/31/2020	N/A	-24	-10	-10	N/A
12/31/2019	N/A	-21	-7	-7	N/A
9/30/2019	N/A	-12	-10	-10	N/A
6/30/2019	N/A	-11	-9	-9	N/A
3/31/2019	N/A	-13	-12	-12	N/A
12/31/2018	N/A	-16	-14	-14	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: MTVA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: MTVA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: MTVA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if MTVA's revenue is forecast to grow faster than the US market.

High Growth Revenue: MTVA is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if MTVA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/05 06:26
End of Day Share Price	2025/01/03 00:00
Earnings	2024/09/30
Annual Earnings	2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

MetaVia Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Antonio Arce	H.C. Wainwright & Co.
Raghuram Selvaraju	H.C. Wainwright & Co.
Robert LeBoyer	Ladenburg Thalmann & Company

MetaVia Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased by 35% to US$17.33

No longer forecast to breakeven

No longer forecast to breakeven

Price target decreased to US$16.00

Recent updates

Price target decreased by 35% to US$17.33

MetaVia Inc. Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH

New major risk - Financial position

NeuroBo Pharmaceuticals, Inc. Completes Last Patient Last Visit in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH

Here's Why We're A Bit Worried About NeuroBo Pharmaceuticals' (NASDAQ:NRBO) Cash Burn Situation

Neurobo Pharmaceuticals Announces Positive Top-Line Data from the Sad Part 1 of Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. announced that it has received $17.000005 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals, Inc. Doses First Patient in the MAD Part 2 of its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3.000001 million.

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 07, 2024

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 1 Clinical Trial Evaluating Da-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Completes Enrollment of Part 1 of Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals, Inc. Receives Safety Review Committee Approval to Continue with Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment

Neurobo Pharmaceuticals Reports Positive Pre-Clinical Safety Data of Da-1241 in Combination with Sitagliptin and Opens Enrollment for Part 2 of Its Phase 2A Clinical Trial Evaluating Da-1241 for the Treatment of Mash

NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity

NeuroBo Pharmaceuticals, Inc. Appoints James P. Tursi to its Board of Directors and as Member of Nominating and Corporate Governance Committee

NeuroBo Pharmaceuticals, Inc. Appoints Marshall H. Woodworth as Acting Chief Financial Officer

NeuroBo Pharmaceuticals, Inc. Announces Resignation of Na Yeon (Irene) Kim from the Board of Directors

NeuroBo Pharmaceuticals, Inc. Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of Nash

NeuroBo Pharmaceuticals, Inc. Announces Executive Changes

NeuroBo Pharmaceuticals Receives 180-Day Extension to February 5, 2024 from Nasdaq to Regain Compliance with the Minimum Bid Price Requirement

Neurobo Pharmaceuticals, Inc. Receives First Site IRB Approval for Its Phase 2A Clinical Trial Evaluating DA-1241 for the Treatment of NASH

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 28, 2023

Neurobo Pharmaceuticals, Inc. Appoints Pharmaceutical Industry Executive, Mark A. Glickman, to Its Board of Directors

NeuroBo Pharmaceuticals Receives Non-Compliance Notice from Nasdaq

NeuroBo Pharmaceuticals, Inc. Appoints Joseph Hooker as President

NeuroBo Pharmaceuticals, Inc. announced that it has received $15 million in funding from Dong-A ST Co., Ltd.

NeuroBo Pharmaceuticals Compliant with All Applicable Nasdaq Listing Criteria

NeuroBo Pharmaceuticals regains compliance with Nasdaq minimum bid price requirement

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $37 million in funding from Dong-A ST Co., Ltd.

Here's Why NeuroBo Pharmaceuticals (NASDAQ:NRBO) Must Use Its Cash Wisely

NeuroBo Pharmaceuticals climbs higher on announcing reverse stock split

NeuroBo Pharmaceuticals, Inc., Annual General Meeting, Jun 09, 2022

Neurobo Pharmaceuticals, Inc. Appoints Matthew Bardin as Senior Vice President Operations

High number of new and inexperienced directors

NeuroBo Pharmaceuticals, Inc. Appoints D. Gordon Strickland to its Board of Directors

NeuroBo Pharmaceuticals: Advancing Therapies For Viral, Neuropathic And Neurodegenerative Diseases

No longer forecast to breakeven

Independent Director Jeong Gyun Oh has left the company

No longer forecast to breakeven

Price target decreased to US$16.00

NeuroBo Pharmaceuticals, Inc.(NasdaqCM:NRBO) dropped from Russell 3000E Index

NeuroBo on track to post a record gain after announcing a special meeting

NeuroBo Pharmaceuticals, Inc. announced delayed annual 10-K filing

NeuroBo Pharmaceuticals, Inc. Announces Board Changes

New 90-day low: US$4.68

NeuroBo Pharmaceuticals, Inc. announced that it expects to receive $10 million in funding

Neurobo Pharmaceuticals, Inc. Announces Executive Changes

Neurobo Pharmaceuticals, Inc. Appoints Akash Bakshi as Class II Director to the Board and Chief Operating Officer and Senior Vice President

New 90-day high: US$6.68

NeuroBo Pharmaceuticals rallies on ANA Therapeutics acquisition

Here's What NeuroBo Pharmaceuticals, Inc.'s (NASDAQ:NRBO) Shareholder Ownership Structure Looks Like

NeuroBo Pharmaceuticals EPS misses by $0.02

New 90-day low: US$5.24

New 90-day low - US$5.80

New 90-day low - US$6.16

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies

Company Analysis and Financial Data Status

Data Sources

Analysis Model and Snowflake

Industry and Sector Metrics

Analyst Sources